Navigation Links
Bionovo Announces Third Quarter 2007 Financial Results

EMERYVILLE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced financial results for the third quarter and nine months ended September 30, 2007.

Third Quarter Results

The company reported revenues for the three months ended September 30, 2007 of $243,375 compared to $3,750 for the same period in 2006. Revenues increased by $239,625 over the comparable period in 2006, representing our National Institute of Health grant drawdown from the Department of Health and Human Services for 2006. Revenues included $3,750 in amortization from the proceeds of our licensing and technology transfer agreement with United Biotechnology Corporation ("UBC") of Taiwan. On October 15, 2007, Bionovo, Inc. terminated its Licensing and Technology Transfer Agreement dated November 3, 2003 (the "Agreement") with UBC of Taiwan. Unamortized deferred revenue of $91,250 will be recognized in the next quarter. Total operating expenses for the three months ended September 30, 2007 were $3.6 million compared to $1.4 million for the same period in 2006.

The company reported a net loss for the three months ended September 30, 2007 of $3.2 million, or $0.05 per share, compared with a net loss of $1.3 million, or $0.03 per share, for the same period in 2006.

Nine Month Results

Revenues for the nine months ended September 30, 2007 were $250,875 compared with $11,250 for the same period in 2006. For the nine months ended September 30, 2007 total operating expenses were $9.9 million compared with $3.8 million for the same period in 2006.

The net loss for the nine months ended September 30, 2007 was $9.2 million, or $0.15 per share, compared with a net loss of $3.7 million, or $0.07 per share, for the same period in 2006. As of September 30, 2007, cash, cash equivalents and short-term investments totaled approximately $12.7 million.

Subsequent Events

On October 31, 2007, Bionovo, Inc. received $24.0 million, net of underwriting discount, from the closing of its public offering of 10.0 million shares of common stock at a price to the public of $2.50 per share and 5.3 million warrants to purchase shares of common stock at $3.50 per share at a price of $0.10 per warrant. Following the offering, the Company will have 76,036,435 outstanding shares of common stock. The underwriters may also purchase up to an additional 1,500,000 shares and warrants to purchase an additional 750,000 shares from Bionovo, Inc. within 30 days from the date of the closing to cover over-allotment of shares and warrants.

Third Quarter Company Highlights

-- Patient enrollment and dosing continues in the Phase 1 portion of the

BZL101 Phase 1/2 clinical trial for advanced metastatic breast cancer.

-- Bionovo presented data on BZL101 at the AACR-NCI-EORTC International

Conference on Molecular Targets and Cancer Therapeutics showing that

BZL101 selectively elicits its cytotoxic activity on cancer cells while

avoiding normal cells through the inhibition of glycolysis.

-- The results of the MF101 Phase 1/2 clinical trial were the top scoring

abstract at the North American Menopause Society's 18th Annual Meeting.

Principal Investigator, Dr. Deborah Grady delivered the oral

presentation, entitled, A Novel Selective Estrogen Receptor-Beta

Agonist for the Treatment of Menopausal Hot Flushes.

-- Tom Chesterman was appointed as Senior Vice President and Chief

Financial Officer in July 2007, bringing over 15 years of proven

success and leadership in the biotechnology and telecommunications

industries to the company.

Upcoming Conferences

-- December 6-7: BMO Healthcare Conference, New York City

The unaudited pro-forma balance sheet information in the accompanying balance sheet is provided as a result of the significant changes in the Company's capital structure subsequent to the balance sheet date and assumes the transactions noted above that were completed subsequent to September 30, 2007 had occurred as of September 30, 2007.

A full quarterly financial report on Form 10-Q is expected to be filed by Tuesday, November 13.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Bionovo, Inc. (formerly Lighten Up Enterprises International, Inc.)

(A Development Stage Company)

Condensed Statements of Operations




Feb. 1,

Three Three Nine Nine 2002

months months months months (Date of

ended ended ended ended inception)

Sept. Sept. Sept. Sept. To Sept.

30, 30, 30, 30, 30,

2007 2006 2007 2006 2007

Revenues $243,375 $3,750 $250,875 $11,250 $328,615



Research and

development 2,444,674 970,791 7,212,445 2,617,599 13,066,907

General and


trative 1,118,482 336,894 2,575,646 995,101 5,358,670

Sales and

marketing 10,920 66,550 113,600 233,017 498,777

Merger cost 1,964,065

Total operating

expenses 3,574,076 1,374,235 9,901,691 3,845,717 20,888,419

Loss from

operations (3,330,701) (1,370,485) (9,650,816)(3,834,467) (20,559,804)

Change in fair

value of warrant

liability - - - - 831,288

Interest income 170,272 58,566 517,958 189,655 928,430

Interest expense (42,370) (17,843) (68,898) (31,426) (219,332)

Other income

(expense) (5,241) - (5,241) - (30,945)

Income (loss)

before income

tax (3,208,040) (1,329,762) (9,206,997) (3,676,238) (19,050,363)

Income tax

provision - (800) (2,400) (2,400) (8,000)

Net loss $(3,208,040)$(1,330,562)$(9,209,397)$(3,678,638)$(19,058,363)

Basic and diluted

net loss per

common share $(0.05) $(0.03) $(0.15) $(0.07) $(0.55)

Shares used in

computing basic

and diluted net

loss per common

share 65,571,108 51,182,450 63,368,561 49,467,016 34,670,667

Bionovo, Inc. (formerly Lighten Up Enterprises International, Inc.)

(A Development Stage Company)

Consolidated Balance Sheet

Pro Forma

(Note 13)

September 30, September 30, December 31,

2007 2007 2006

(Unaudited) (Unaudited) (Note 1)


Current assets:

Cash and cash equivalents $36,584,259 $12,551,881 $2,571,439

Short-term investments 193,975 193,975 484,017

Receivables from officers

and employees 1,796 1,796 1,796

Prepaid expenses and

other current assets 547,643 547,643 183,528

Total current assets 37,327,673 13,295,295 3,240,780

Property and equipment, net 3,455,147 3,455,147 1,672,904

Other assets and patent

pended, net 166,376 166,376 58,613

Total assets $40,949,196 $16,916,818 $4,972,297


Current liabilities:

Accounts payable $750,265 $750,265 $780,393

Accrued clinical costs 24,900 24,900 -

Accrued compensation and

benefits 435,809 435,809 -

Current portion of lease

obligation 710,643 710,643 292,333

Deferred revenue 15,000 15,000 15,000

Total current liabilities 1,936,617 1,936,617 1,087,726

Non-current portion of lease

obligation 693,839 693,839 300,741

Non-current portion of

deferred revenue 76,250 76,250 87,500

Commitments and contingencies

Shareholders' equity:

Common stock, $0.0001 par value,

190,000,000 shares authorized;

issued and outstanding shares:

66,036,435 at September 30, 2007;

51,337,224 at December 31, 2006;

and 76,036,435 on an unaudited

pro forma basis. 7,602 6,602 5,134

Additional paid-in capital 57,293,251 33,261,873 13,340,163

Accumulated deficit (19,058,363) (19,058,363) (9,848,967)

Total shareholders'

equity 38,242,490 14,210,112 3,496,330

Total liabilities and

shareholders' equity $40,949,196 $16,916,818 $4,972,297

* The balance sheet at December 31, 2006 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

SOURCE Bionovo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
Breaking Biology Technology:
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):